 <h1>IsonaRif Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>isoniazid / rifampin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about isoniazid / rifampin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name IsonaRif.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to isoniazid/rifampin: oral capsule</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Severe and sometimes fatal hepatitis has been reported with isoniazid therapy and may occur even after many months of treatment. The risk for hepatitis generally increases with advancing age and alcohol use. Monthly clinical evaluation and liver function tests should be performed. Instruct patients to report immediately any of the prodromal symptoms of hepatitis, such as fatigue, weakness, malaise, anorexia, nausea, or vomiting. If these symptoms appear or if signs suggestive of hepatic damage are detected, isoniazid should be discontinued promptly. If isoniazid must be reinstituted, it should be reinstituted only after symptoms and laboratory abnormalities have cleared. The drug should be restarted in very small and gradually increasing doses and should be withdrawn immediately if there is any indication of recurrent liver involvement. Treatment should be deferred in persons with acute hepatic diseases.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, isoniazid / rifampin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking isoniazid / rifampin:</p><p>
<i>More common</i>
</p><ul>
<li>Clumsiness or unsteadiness</li>
<li>dark urine</li>
<li>loss of appetite</li>
<li>nausea and vomiting</li>
<li>numbness, tingling, burning, or pain in the hands and feet</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>difficult breathing</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>itching, skin rash and redness</li>
<li>muscle and bone pain</li>
<li>shivering</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloody or cloudy urine</li>
<li>blurred vision or loss of vision, with or without eye pain</li>
<li>convulsions (seizures)</li>
<li>depression</li>
<li>greatly decreased frequency of urination or amount of urine</li>
<li>mood or mental changes</li>
<li>sore throat</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of isoniazid / rifampin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>stomach pain or upset</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Sore mouth or tongue</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to isoniazid / rifampin: oral capsule</i></p><h3>General</h3><p>Doses greater than 600 mg of rifampin given once or twice weekly have resulted in a higher incidence of adverse reactions, including the "flu syndrome" (fever, chills, malaise); hematopoietic reactions (leukopenia, thrombocytopenia, acute hemolytic anemia); shortness of breath; shock; anaphylaxis; renal failure; and cutaneous, gastrointestinal, and hepatic reactions.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Vasculitis</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Flushing, decreased blood pressure<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, Stevens-Johnson syndrome, Toxic Epidermal Necrolysis (TEN), rash</p>
<p></p>
<p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Acne, exfoliative dermatitis, pemphigus</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Erythema multiforme, skin reaction, pruritus, pruritic rash, urticaria, allergic dermatitis, pemphigoid, sweat discoloration, cutaneous reactions<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Gynecomastia, hyperglycemia</p>
<p></p>
<p>Rifampin:</p>
<p><b>Rare</b> (less than 0.1%): Adrenal insufficiency</p>
<p><b>Frequency not reported</b>: Menstrual disorder/disturbances<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Nausea, vomiting, epigastric distress, diarrhea</p>
<p></p>
<p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Constipation, dry mouth, pancreatitis</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Gastrointestinal disorder, abdominal discomfort, heartburn, flatulence, cramps, pseudomembranous colitis, sore mouth, sore tongue<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Thrombocytopenia, eosinophilia, agranulocytosis, hemolytic anemia</p>
<p></p>
<p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Anemia, aplastic anemia, lymphadenopathy</p>
<p></p>
<p>Rifampin:</p>
<p><b>Uncommon</b> (0.1% to 1%): Leukopenia</p>
<p><b>Rare</b> (less than 0.1%): Disseminated intravascular coagulation</p>
<p><b>Frequency not reported</b>: Decreased hemoglobin<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatitis, elevated serum transaminases (SGOT, SGPT), bilirubinemia, bilirubinuria, jaundice</p>
<p></p>
<p>Rifampin:</p>
<p><b>Common</b> (1% to 10%): Elevated alkaline phosphatase</p>
<p><b>Rare</b> (less than 0.1%): Abnormal liver function, shock-like syndrome with hepatic involvement</p>
<p><b>Frequency not reported</b>: Hyperbilirubinemia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Rifampin:</p>
<p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Pellagra, pyridoxine deficiency, metabolic acidosis</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Decreased appetite, anorexia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Systemic lupus erythematosus-like syndrome, rheumatic syndrome</p>
<p></p>
<p>Rifampin:</p>
<p><b>Rare</b> (less than 0.1%): Myopathy</p>
<p><b>Frequency not reported</b>: Muscle weakness, bone pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Peripheral neuropathy associated with isoniazid is dose-dependent, most often occurs in malnourished patients and in patients predisposed to neuritis (such as alcoholics and diabetics), and generally follows paresthesias of the hands and feet.  The rate is higher in slow acetylators.<sup>[Ref]</sup></p><p>Isoniazid:</p>
<p><b>Common</b> (1% to 10%): Peripheral neuropathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Convulsions, toxic encephalopathy, optic neuritis and atrophy, memory impairment </p>
<p><b>Frequency not reported</b>: Vertigo, polyneuritis (presenting as paresthesia, muscle weakness, loss of tendon reflexes)</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Headache, drowsiness, cerebral hemorrhage, ataxia, dizziness, inability to concentrate, muscular weakness, pains in extremities, generalized numbness<sup>[Ref]</sup></p><h3>Ocular</h3><p>Rifampin:</p>
<p><b>Frequency not reported</b>: Tear discoloration, visual disturbances, conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Fever</p>
<p></p>
<p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Anti-nuclear antibodies</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Influenza-like syndrome, post-partum hemorrhage, fetal-maternal hemorrhage, porphyria, edema, fatigue, facial edema, edema of the extremities, shock<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Isoniazid:</p>
<p><b>Frequency not reported</b>: Toxic psychosis</p>
<p></p>
<p>Rifampin:</p>
<p><b>Frequency not reported</b>: Psychotic disorder/psychoses, mental confusion, behavioral changes<sup>[Ref]</sup></p><h3>Renal</h3><p>Rifampin:</p>
<p><b>Rare</b> (less than 0.1%): Hemolysis, hemoglobinuria, hematuria, interstitial nephritis, acute tubular necrosis, renal insufficiency, acute renal failure</p>
<p><b>Frequency not reported</b>: Acute kidney injury, chromaturia, increased blood creatinine, elevated BUN, elevated serum uric acid<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Rifampin:</p>
<p><b>Frequency not reported</b>: Dyspnea, wheezing, discolored sputum, shortness of breath<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Rifamate (isoniazid-rifampin)." Aventis Pharmaceuticals, Kansas City, MO. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about IsonaRif (isoniazid / rifampin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: antituberculosis combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>IsonaRif &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Rifamate</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Tuberculosis, Active</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to isoniazid / rifampin: oral capsule</i></p><h3>General</h3><p>Doses greater than 600 mg of rifampin given once or twice weekly have resulted in a higher incidence of adverse reactions, including the "flu syndrome" (fever, chills, malaise); hematopoietic reactions (leukopenia, thrombocytopenia, acute hemolytic anemia); shortness of breath; shock; anaphylaxis; renal failure; and cutaneous, gastrointestinal, and hepatic reactions.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Vasculitis</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Flushing, decreased blood pressure<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, Stevens-Johnson syndrome, Toxic Epidermal Necrolysis (TEN), rash</p><p></p><p>Isoniazid:</p><p><b>Frequency not reported</b>: Acne, exfoliative dermatitis, pemphigus</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Erythema multiforme, skin reaction, pruritus, pruritic rash, urticaria, allergic dermatitis, pemphigoid, sweat discoloration, cutaneous reactions<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Isoniazid:</p><p><b>Frequency not reported</b>: Gynecomastia, hyperglycemia</p><p></p><p>Rifampin:</p><p><b>Rare</b> (less than 0.1%): Adrenal insufficiency</p><p><b>Frequency not reported</b>: Menstrual disorder/disturbances<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Nausea, vomiting, epigastric distress, diarrhea</p><p></p><p>Isoniazid:</p><p><b>Frequency not reported</b>: Constipation, dry mouth, pancreatitis</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Gastrointestinal disorder, abdominal discomfort, heartburn, flatulence, cramps, pseudomembranous colitis, sore mouth, sore tongue<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Thrombocytopenia, eosinophilia, agranulocytosis, hemolytic anemia</p><p></p><p>Isoniazid:</p><p><b>Frequency not reported</b>: Anemia, aplastic anemia, lymphadenopathy</p><p></p><p>Rifampin:</p><p><b>Uncommon</b> (0.1% to 1%): Leukopenia</p><p><b>Rare</b> (less than 0.1%): Disseminated intravascular coagulation</p><p><b>Frequency not reported</b>: Decreased hemoglobin<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatitis, elevated serum transaminases (SGOT, SGPT), bilirubinemia, bilirubinuria, jaundice</p><p></p><p>Rifampin:</p><p><b>Common</b> (1% to 10%): Elevated alkaline phosphatase</p><p><b>Rare</b> (less than 0.1%): Abnormal liver function, shock-like syndrome with hepatic involvement</p><p><b>Frequency not reported</b>: Hyperbilirubinemia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Rifampin:</p><p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Isoniazid:</p><p><b>Frequency not reported</b>: Pellagra, pyridoxine deficiency, metabolic acidosis</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Decreased appetite, anorexia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Isoniazid:</p><p><b>Frequency not reported</b>: Systemic lupus erythematosus-like syndrome, rheumatic syndrome</p><p></p><p>Rifampin:</p><p><b>Rare</b> (less than 0.1%): Myopathy</p><p><b>Frequency not reported</b>: Muscle weakness, bone pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Peripheral neuropathy associated with isoniazid is dose-dependent, most often occurs in malnourished patients and in patients predisposed to neuritis (such as alcoholics and diabetics), and generally follows paresthesias of the hands and feet.  The rate is higher in slow acetylators.<sup>[Ref]</sup></p><p>Isoniazid:</p><p><b>Common</b> (1% to 10%): Peripheral neuropathy</p><p><b>Uncommon</b> (0.1% to 1%): Convulsions, toxic encephalopathy, optic neuritis and atrophy, memory impairment </p><p><b>Frequency not reported</b>: Vertigo, polyneuritis (presenting as paresthesia, muscle weakness, loss of tendon reflexes)</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Headache, drowsiness, cerebral hemorrhage, ataxia, dizziness, inability to concentrate, muscular weakness, pains in extremities, generalized numbness<sup>[Ref]</sup></p><h3>Ocular</h3><p>Rifampin:</p><p><b>Frequency not reported</b>: Tear discoloration, visual disturbances, conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Fever</p><p></p><p>Isoniazid:</p><p><b>Frequency not reported</b>: Anti-nuclear antibodies</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Influenza-like syndrome, post-partum hemorrhage, fetal-maternal hemorrhage, porphyria, edema, fatigue, facial edema, edema of the extremities, shock<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Isoniazid:</p><p><b>Frequency not reported</b>: Toxic psychosis</p><p></p><p>Rifampin:</p><p><b>Frequency not reported</b>: Psychotic disorder/psychoses, mental confusion, behavioral changes<sup>[Ref]</sup></p><h3>Renal</h3><p>Rifampin:</p><p><b>Rare</b> (less than 0.1%): Hemolysis, hemoglobinuria, hematuria, interstitial nephritis, acute tubular necrosis, renal insufficiency, acute renal failure</p><p><b>Frequency not reported</b>: Acute kidney injury, chromaturia, increased blood creatinine, elevated BUN, elevated serum uric acid<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Rifampin:</p><p><b>Frequency not reported</b>: Dyspnea, wheezing, discolored sputum, shortness of breath<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Rifamate (isoniazid-rifampin)." Aventis Pharmaceuticals, Kansas City, MO. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about IsonaRif (isoniazid / rifampin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: antituberculosis combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>IsonaRif &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Tuberculosis, Active</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>